Novo Nordisk initiates catch-up efforts, share price surpasses significant resistance level
Novo Nordisk's stock is on an upward trajectory, reaching a new high of 380.00 Danish Kroner on Thursday. This positive trend is supported by further positive study news and renewed optimistic analyst views.
The focus of Novo Nordisk's research and development strategy remains on obesity, diabetes, and related comorbidities. Recently, the company has made significant strides with its oral Semaglutid, a potential game-changer in the treatment of obesity.
In a study published by the New England Journal of Medicine, oral Semaglutid (Wegovy in tablet form) led to an average weight loss of 16.6% in adults with obesity or overweight without diabetes after 64 weeks. Over a third of participants lost more than 20% of their weight, a promising result in the fight against obesity.
The safety profile of oral Semaglutid matches that of injectable Wegovy, with side effects mainly transient nausea and vomiting. Novo Nordisk has submitted an FDA approval application for oral Semaglutid, with a decision expected by the end of the year. If approved, production will be fully based in the US.
In a significant development, Novo Nordisk also reported strong results from the REACH real-world study. Ozempic (once-weekly injectable Semaglutid) was associated with a 23% lower risk of severe cardiovascular events like heart attack or stroke compared to Dulaglutide, a competing drug from US-based Eli Lilly.
Ozempic demonstrates significantly better cardiovascular risk reduction properties than Dulaglutide, providing Novo Nordisk with a competitive edge in the market. This news has further bolstered investor confidence in the company.
The current analyst from JPMorgan covering Novo Nordisk is Richard Vosser, who maintains a Buy rating on the stock with a target price of DKK 500. JPMorgan continues to advise customers to buy Novo Nordisk shares as of September 2025. Analyst Richard Vosser highlighted that the management has reaffirmed its research and development strategy at the EASD 2025 diabetes conference.
Notably, the board and majority shareholder of the publisher Boersenmedien AG, Mr. Bernd Foertsch, also holds positions in Novo Nordisk. DER AKTIONÄR remains optimistic about Novo Nordisk's stock, with the stock surpassing its August high of 371.85 Danish Kroner.
Newcomers with foresight can still jump in on Novo Nordisk's stock, as it continues to perform well and promises exciting developments in the field of diabetes and obesity treatment. The stock reached a new high since late July, reflecting the market's growing confidence in Novo Nordisk and its innovative products.
